Eli Lilly claims a TKO in its long-running title fight with Novo Nordisk for the blockbuster diabetes market — but there’s a hitch
Eli Lilly isn’t just gunning for a better diabetes drug in tirzepatide. They want to cut ahead of Novo Nordisk’s blockbuster rival Ozempic (semaglutide) on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
